China Facial Injectable Market Size & Outlook, 2026-2033
Global Market
Related Markets
China facial injectable market highlights
- The China facial injectable market generated a revenue of USD 2,301.9 million in 2025 and is expected to reach USD 4,716.9 million by 2033.
- The China market is expected to grow at a CAGR of 9.5% from 2026 to 2033.
- In terms of segment, botulinum toxin (botox) was the largest revenue generating product in 2025.
- PN/PDRN is the most lucrative product segment registering the fastest growth during the forecast period.
Facial injectable market data book summary
| Market revenue in 2025 | USD 2,301.9 million |
| Market revenue in 2033 | USD 4,716.9 million |
| Growth rate | 9.5% (CAGR from 2026 to 2033) |
| Largest segment | Botulinum toxin (botox) |
| Fastest growing segment | PN/PDRN |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Collagen and PMMA Microspheres, Hyaluronic Acid, Calcium Hydroxylapatite (CaHA), PLLA, PCL, PN/PDRN, Botulinum Toxin (Botox), Exosome |
| Key market players worldwide | AbbVie Inc, Medytox, Merz Pharma, Revance Therapeutics Inc, Galderma, Sinclair Pharma plc |
Other key industry trends
- In terms of revenue, China accounted for 19.5% of the global facial injectable market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China facial injectable market is projected to lead the regional market in terms of revenue in 2033.
- Thailand is the fastest growing regional market in Asia Pacific and is projected to reach USD 296.7 million by 2033.
China's Facial Injectable Market is witnessing significant growth, driven by expanding product availability, increasing aesthetic awareness, and growing consumer demand for non-invasive treatments. In May 2024, Galderma launched Restylane VOLYME in China, addressing mid-face aging concerns with its Shape Up Holistic Individualized Treatment (HIT) approach, reflecting a commitment to personalized aesthetic solutions.
Additionally, in September 2024, Allergan Aesthetics introduced BOTOX Cosmetic for the treatment of masseter muscle prominence (MMP), marking it as the first neurotoxin approved in China for this indication. With China’s medical aesthetics market outpacing global growth trends and relatively low market penetration, there remains vast potential for expansion.
As global leaders continue investing in advanced injectables and regulatory approvals increase, China's Facial Injectable Market is set for robust growth, fueled by a rising middle-class population, higher disposable incomes, and a growing emphasis on facial aesthetics.
No credit card required*
Publish Date: May 06, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Facial Injectable Market Scope
Facial Injectable Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Revance Therapeutics Inc | View profile | 597 | 1222 Demonbreun Street, Suite 2000, Nashville, TN, United States, 37203 | www.revance.com |
| Merz Pharma | View profile | 5001-10000 | Deutsch, Sachsen, Germany, Europe | www.merz.com |
| Sinclair Pharma plc | View profile | 501-1000 | London, England, United Kingdom, Europe | www.sinclairpharma.com/ |
| Medytox | View profile | 501-1000 | Seoul, Seoul-t'ukpyolsi, South Korea, Asia | www.medytox.com/page/company_en?site_id=en |
| Ipsen SA | View profile | 5,325 | 65 Quai Georges Gorse, Billancourt Cedex, Boulogne, France, 92100 | www.ipsen.com |
| Galderma | View profile | 10001+ | Lausanne, Vaud, Switzerland, Europe | www.galderma.com |
China Facial Injectable Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Facial Injectable Market Outlook will help companies and investors design strategic landscapes.
Botulinum Toxin (Botox) was the largest segment with a revenue share of 49.08% in 2025.
Horizon Databook has segmented the China facial injectable market based on collagen and pmma microspheres, hyaluronic acid, calcium hydroxylapatite (caha), plla, pcl, pn/pdrn, botulinum toxin (botox), exosome covering the revenue growth of each sub-segment from 2021 to 2033.
China's Facial Injectable Market is witnessing significant growth, driven by expanding product availability, increasing aesthetic awareness, and growing consumer demand for non-invasive treatments. In May 2024, Galderma launched Restylane VOLYME in China, addressing mid-face aging concerns with its Shape Up Holistic Individualized Treatment (HIT) approach, reflecting a commitment to personalized aesthetic solutions.
Additionally, in September 2024, Allergan Aesthetics introduced BOTOX Cosmetic for the treatment of masseter muscle prominence (MMP), marking it as the first neurotoxin approved in China for this indication. With China’s medical aesthetics market outpacing global growth trends and relatively low market penetration, there remains vast potential for expansion.
As global leaders continue investing in advanced injectables and regulatory approvals increase, China's Facial Injectable Market is set for robust growth, fueled by a rising middle-class population, higher disposable incomes, and a growing emphasis on facial aesthetics.
- China Facial Injectable Market Product Outlook (Revenue, USD Million , 2021-2033)
- Collagen and PMMA Microspheres
- Hyaluronic Acid
- Calcium Hydroxylapatite (CaHA)
- PLLA
- PCL
- PN/PDRN
- Botulinum Toxin (Botox)
- Exosome
- China Facial Injectable Market Applications Outlook (Revenue, USD Million , 2021-2033)
- Wrinkle Correction
- Lip Augmentation
- Facial Contouring
- Scar Treatment
- Volume Loss Restoration
- Others
- China Facial Injectable Market End Use Outlook (Revenue, USD Million , 2021-2033)
- MedSpas
- Aesthetic Surgery Centers
- Hospitals
- Others
Reasons to subscribe to Facial Injectable Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Facial Injectable Market Outlook databook
- Our clientele includes a mix of Facial Injectable Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China Facial Injectable Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into China Facial Injectable Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
China Facial Injectable Market, 2021-2033 (US$M)
China facial injectable market statistics, by product, 2021-2033 (US$M)
